Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Crossy who wrote (5933)	3/18/2002 10:23:13 AM
From: tuck	Read Replies (2) \| Respond to of 52153

I always thought it was hilarious that Japan Tobacco is Cell Genesys' partner for their lung cancer vaccine. Message 17013169 CEGE recently received a milestone payment from them. No mention of Nichiiko Pharma. Cheers, Tuck

To: Crossy who wrote (5933)	3/18/2002 9:52:36 PM
From: John Metcalf	Read Replies (1) \| Respond to of 52153

Crossy, thanks for the information. As I read it, JT only sold the over-the-counter part of its drug operations, and did so in order to focus on drug development: jtnet.ad.jp You asked if JT's effort was substantial. They partially funded development of Agouron's Viracept for HIV. They owned 50% of Xenotech, developer of Xenomouse fully human antibody technology (which now belongs to ABGX). They sold a crop technology to Dow Chem. I don't know how much of the research was done by JT, but someone over there has made some good decisions.

To: Crossy who wrote (5933)	3/18/2002 10:04:25 PM
From: John Metcalf	Respond to of 52153

A little more on JT/Nichiiko, from JT's annual report (available in English in pdf format). jtnet.ad.jp In the pharmaceuticals business, JT focused on strengthening its own R&D capabilities in the field of prescription drugs, and also conducted R&D jointly with other corporations overseas. We teamed up with US biotechnology company Tularik Inc. to establish Tularik Pharmaceutical Company, a research facility in California, in order to strengthen our overseas R&D capabilities. At present, nine drugs are in the clinical development pipeline. Sales of the anti-HIV viral drug that we developed jointly with Agouron Pharmaceuticals, Inc. of the United States (on sale in the U.S., Europe, Japan and elsewhere) declined somewhat due to increased competition. Operations at Torii Pharmaceuticals Co., Ltd. were generally strong due to increased of their mainstay product Futhan, an injectable protease inhibitor. We were previously active in marketing OTC drugs and health-related products through LIFIX Inc. however, JT decided to our pharmaceuticals operations solely on prescription drugs, and primary products in the field of OTC drugs operations were transferred to Nichiiko Pharmaceutical Co., Ltd with the exception of nutritious drinks which will be transferred to our foods business in February 2001. This is the first time I've heard the brand-name "Futhan"; uncomfortably close to "futon".